(Q54376271)

29 May 2018

title

Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. (English)

1 reference

29 May 2018

1 reference

Ying-Li Lin

1

1 reference

29 May 2018

Xiao-Qiang Liu

2

1 reference

29 May 2018

Wen-Ping Li

3

1 reference

29 May 2018

Guang Sun

4

1 reference

29 May 2018

Chun-Ting Zhang

5

1 reference

29 May 2018

publication date

24 April 2011

1 reference

29 May 2018

International Urology and Nephrology

published in

1 reference

29 May 2018

volume

44

1 reference

29 May 2018

issue

1

1 reference

29 May 2018

page(s)

111-117

1 reference

29 May 2018

Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

The present and future burden of urinary bladder cancer in the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Bladder cancer in 2010: how far have we come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Defining optimal therapy for muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

DNA methylation and cancer diagnosis: new methods and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Epigenetic markers as promising prognosticators for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Epigenetics in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Guidelines on bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Epigenetic biomarkers in urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Bladder cancer: clinical and pathological profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Effect of DNA methylation on identification of aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

DNA methylation markers and early recurrence in stage I lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-011-9961-6

CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features

1 reference

12 December 2020

The role of hLHX6-HMR as a methylation biomarker for early diagnosis of cervical cancer

1 reference

12 December 2020

1 reference

12 December 2020

A gene hypermethylation profile of human cancer

1 reference

12 December 2020

Identification of candidate epigenetic biomarkers for ovarian cancer detection

1 reference

12 December 2020

Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium

1 reference

12 December 2020

Cadherin 13 in cancer.

1 reference

12 December 2020

Natural history and treatment of low and high risk superficial bladder tumors

1 reference

12 December 2020

Methylation pattern of CDH13 gene in digestive tract cancers

1 reference

12 December 2020

Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma.

1 reference

12 December 2020

The global burden of urinary bladder cancer.

1 reference

12 December 2020

10.1007/S11255-011-9961-6

Identifiers

DOI

1 reference

29 May 2018

PubMed ID

21516472

1 reference

29 May 2018